Fund comparison · from official SEC filings

BIPIX vs LABU: how much do they overlap?

BIOTECHNOLOGY ULTRASECTOR PROFUND and Direxion Daily S&P Biotech Bull 3X Shares
Holdings overlap
77%
of assets, by weight
Shared positions
145
of 147 / 154 holdings
BIPIX expense ratio
1.52%
net, per year
LABU expense ratio
0.93%
net, per year
BIPIX and LABU are largely redundant — holding both means most of your money tracks the same underlying companies.
Shared holdings
Company
BIPIX
LABU
?
N/A
27.27%
7.26%
1
1JKAPELLIS PHARMACEUTICALS INC
1.32%
1.44%
R
RVMDREVOLUTION MEDICINES INC
1.17%
1.27%
T
TVTXTRAVERE THERAPEUTICS INC
1.15%
1.25%
A
ARWRARROWHEAD PHARMACEUTICALS IN
1.02%
1.11%
T
TWSTTWIST BIOSCIENCE CORP
1.00%
1.10%
S
SMMTSUMMIT THERAPEUTICS INC
0.99%
1.09%
A
ALKSALKERMES PLC
0.98%
1.07%
T
TGTXTG THERAPEUTICS INC
0.97%
1.06%
M
MDGLMADRIGAL PHARMACEUTICALS INC
0.97%
1.06%
B
BEAMBEAM THERAPEUTICS INC
0.94%
1.02%
A
APGEAPOGEE THERAPEUTICS INC
0.89%
0.98%
S
SRRKSCHOLAR ROCK HOLDING CORP
0.87%
0.95%
P
PRAXPRAXIS PRECISION MEDICINES I
0.86%
0.95%
E
EXELEXELIXIS INC
0.86%
0.94%
M
MIRMMIRUM PHARMACEUTICALS INC
0.85%
0.93%
U
UTHRUNITED THERAPEUTICS CORP
0.84%
0.92%
N
NTRANATERA INC
0.84%
0.92%
C
CELCCELCUITY INC
0.84%
0.92%
C
CRSPCRISPR THERAPEUTICS AG
0.84%
0.92%
K
KRYSKRYSTAL BIOTECH INC
0.83%
0.91%
P
PTGXPROTAGONIST THERAPEUTICS INC
0.83%
0.90%
N
NBIXNEUROCRINE BIOSCIENCES INC
0.82%
0.89%
I
INCYINCYTE CORP
0.81%
0.89%
C
CGONCG ONCOLOGY INC
0.81%
0.89%
Only in BIPIX
A
AGPXXINVESCO GVT & AGNCY-INST
2.01%
C
CN2CATALYST PHARMACEUTICALS INC
0.61%
Only in LABU
?
DREYFUS GOVERNMENT CASH MANAGE
7.43%
?
GOLDMAN FINANCIAL
6.27%
?
GOLDMAN SACHS LIQ ES FD A
1.71%
?
Catalyst Pharmaceuticals Inc.
0.66%
?
INHIBRX INC CVR
0.00%
?
DREYFUS
0.00%
?
VERVE THERAPEUTICS INC (CVR)
0.00%
?
NOVOB DC CVR
0.00%
O
OABIOMNIAB INC
0.00%
Hold BIPIX and LABU together? See your combined true holdings, overlap, and blended fees — free, no signup.
Unwrap your portfolio →
Data source: official SEC Form N-PORT filings from each fund. Fund holdings are disclosed quarterly and may reflect a 60-day reporting delay.
Informational and educational only — not investment advice.